Why the study?
The full spectrum of COVID-19 cardiac manifestations remains unclear, prompting this study to examine the prevalence of acute cardiac injury and associated mortality among infected patients.
Does acute cardiac injury increase mortality in hospitalized patients with COVID-19?
Does acute cardiac injury increase mortality in hospitalized patients with COVID-19?
Acute cardiac injury is prevalent in approximately one-third of hospitalized COVID-19 patients and is associated with a more than three-fold increased risk of mortality.
Cardiac injury in COVID-19 may worsen prognosis; meta-analysis leaves open optimal surveillance and management strategies.
Abstract Introduction:The ongoing global pandemic, coronavirus disease 2019 (COVID-19), an illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has ranged from an asymptomatic state to unprecedented number of deaths worldwide. In symptomatic patients, a viral pneumonia can unrelentingly progress to multi-system failure with preferential cardiac tropism. Although the full spectrum of COVID-19 cardiac manifestations is still not clear; acute cardiac injury (ACI) remains a common finding. The goal of our study, not only is to examine the current prevalence of ACI among COVID-19 infected patients but also, the reported mortality.Method:After thoroughly searching the literature for appropriate studies, a systematic review and meta-analysis were performed. Inclusion criteria were 1) Cohort study, case-control study, or case series study. 2) The study population included individuals with COVID-19 3) The presence or absence of cardiac injury was reported in the study 4) Mortality among patients with cardiac injury is reported or can be calculated.Results:Ten studies were included with a total of 1664 patients. The prevalence of ACI was 30.8%. The mortality rate among patients with concurrent COVID-19 and ACI was 53%.Conclusion:ACI can occur in one third of patients with COVID-19. Concurrent COVID-19 and ACI entails a high mortality rate. Serum troponin level can be a good prognostic tool in COVID-19.
No takes yet. Share an insight, caveat, or question.
Salah et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: